Adipotide

Adipotide is a targeted peptidomimetic agent designed to induce fat loss by selectively disrupting the vasculature of white adipose tissue. It functions by binding to prohibitin receptors on blood vessels supplying fat cells, triggering apoptosis and subsequent fat mass reduction. In preclinical trials, it has demonstrated significant reductions in body weight and improvements in insulin sensitivity. Due to its pro-apoptotic mechanism and potential renal toxicity, Adipotide is typically used in short-term cycles under clinical supervision.

• Induces apoptosis in blood vessels of white adipose tissue
• Targets prohibitin complexes

• unit: mg

  low dose: 1

  frequency: daily

  high dose: 5

  standard dose: 3

  administration route: Subcutaneous (SQ)

• Recommended frequency: Daily injection. Suggested cycle length: 2–4 weeks max due to potential renal and liver stress. Follow with a recovery period of at least 4–6 weeks. Avoid stacking with hepatotoxic or nephrotoxic agents during active cycle.

common: ["Injection site reactions"]

warnings: ["Potential liver toxicity","Renal impairment"]

long term: ["Unknown"]

sequence: CKGGRAKDC

half life: 4 hours

degradation: Primarily degraded in the liver.

molecular weight: 2220

molecular formula: C111H204N36O28

tissue specificity: Affects primarily the vasculature of white adipose tissues.

• A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys.preclinicalPMID 22072637 ↗
• A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication.preclinicalPMID 23871959 ↗